Obesity Clinical Trials in Albany, New York

5 studies are recruiting for obesity in Albany, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity

   This trial will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection frac…

   Stage

   Phase 3

   Ages

   18 to 99

   Site

   Capital Cardiology Associates, Albany, New York

   Locations

   657 in total

   Run by

   Amgen

   See if you can join NCT07037459 on ClinicalTrials.gov

2. A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

   This is randomized, double-blind, placebo-controlled study of the long-term efficacy, safety, and tolerability of multiple doses of aleniglipron in participants living with overweight or obesity and T2DM. Participants will be randomized to aleniglipron or placebo for a total of 76 weeks of treatmen…

   Stage

   Phase 3

   Ages

   18 to 79

   Site

   ACCOMPLISH-2 Research Site, Albany, New York

   Locations

   74 in total

   Run by

   Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

   See if you can join NCT07654374 on ClinicalTrials.gov

3. Efficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes

   The primary objective of this study is to demonstrate that ribupatide (KAI-9531) subcutaneous (SC) injection once weekly is superior to semaglutide SC once weekly and to placebo SC once weekly on percent change in body weight.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Kailera Clinical Site, Albany, New York

   Locations

   59 in total

   Run by

   Kailera

   See if you can join NCT07284979 on ClinicalTrials.gov

4. A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity

   This study is being done to look at the safety and effect of NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight when compared to placebo. The purpose of this clinical study is to f…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Capital Cardiology Associates_Albany, Albany, New York

   Locations

   838 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT07567001 on ClinicalTrials.gov

5. Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

   Study GSBR-1290-12 is a Phase 3 pivotal, multicenter, global, randomized, placebo-controlled, double-blind study to investigate the long-term efficacy, safety, and tolerability of 3 maintenance doses of aleniglipron once daily (QD) compared with placebo, when used in combination with a reduced-calo…

   Stage

   Phase 3

   Ages

   18 to 79

   Site

   ACCOMPLISH-1 Research Site, Albany, New York

   Locations

   71 in total

   Run by

   Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

   See if you can join NCT07654361 on ClinicalTrials.gov